Clinical Trial: Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome W

Brief Summary: The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond to treatment with Targretin® and one other standard therapy.

Detailed Summary:
Sponsor: Emergent Product Development Seattle LLC

Current Primary Outcome: PGA Score [ Time Frame: Duration of Study ]

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Emergent Product Development Seattle LLC

Dates:
Date Received: August 8, 2005
Date Started: July 2005
Date Completion:
Last Updated: July 24, 2012
Last Verified: July 2012